Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation. Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities. Pro-inflammatory cytokines, which are secreted from immune cells such as neutrophils, macrophages, and B cells, and CD4+ and CD8+ T lymphocyte infiltration in the lungs, in addition to elastases, can cause destruction and dysfunction within the airways. This leads to airflow limitation and causes structural abnormalities such as obstructive bronchiolitis and parenchymal destruction (emphysema). In turn, these changes reduce lung elastic recoil and therefore the ability of the airways to remain open during expiration. Symptoms from such changes include dyspnea, wheezing, chronic cough, and sputum over production, which can impact a patient’s physical and mental well-being. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.
Key Questions Answered
How will the COPD market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018–2028?
What are the most promising late-stage pipeline products for COPD?
How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing COPD product options?
What are the remaining unmet needs in COPD?
What drivers and barriers will affect COPD product sales in the 7MM over the forecast period?

Scope

Overview of COPD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline COPD market revenue from 2018–2028. Annual cost of treatment and major pipeline product sales in this forecast period are included.

Key topics covered include current COPD treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD product sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global COPD market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

During the 10-year forecast period, there are 7 pipeline products that are on track to launch, driving a forecast growth in the 7MM from $10.9B in 2018 to $19.3B in 2028, which represents a CAGR of 5.9%.

The percentage of drug-treated patients (receiving maintenance treatment only) will rise across the 7MM with an average AGR of 1.19% across all COPD severity grades, reaching over 23 million by 2028.

The entry of inhaled corticosteroids/long-acting beta2-agonists/long-acting muscarinic antagonists (ICS/LABA/LAMA) that will include expensive bronchodilators, will continue to take patient share from LABA and LAMA monotherapies, and ICS/LABA dual therapy to simplify treatment management.

The entry of anti-eosinophilic biologics from 2024 will boost overall COPD sales despite the small patient population that these therapies will treat. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price tag.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global COPD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AstraZeneca
GlaxoSmithKline
Regeneron/Sanofi
Novartis
Chiesi
Sunovion
Boehringer Ingelheim
Theravance
Genentech/Roche
Verona Pharmaceuticals
Almirall
Takeda
Kyowa Hakko Kirin
Actavis

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 COPD: Executive Summary

2.1 Sales for COPD by Country, 2018–2028

2.2 GSK continues to dominate the COPD market in 2028

2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Need

2.4 Treatments that Reverse the Progression of COPD Remain Elusive

2.5 Pipeline COPD Treatment to Target a Niche Population

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

4.3 Symptoms

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for COPD (2018 – 2028)

5.5.1 Total Prevalent Cases of COPD

5.5.2 Sex-Specific Total Prevalent Cases of COPD

5.5.3 Age-Specific Total Prevalent Cases of COPD

5.5.4 Diagnosed Prevalent Cases of COPD

5.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD

5.5.6 Age-Specific Diagnosed Prevalent Cases of COPD

5.5.7 Diagnosed Prevalent Cases of COPD by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Disease-Modifying Treatments to Reverse the Progression of COPD

8.3 Identification of Biomarkers that Predict Efficacy

8.4 Observance of GOLD Guidelines Among General Practitioners

8.5 Improved Clinical Trial Design

8.6 Earlier Diagnosis and Recognition of Symptoms

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 IL-4/IL-5 inhibitors

9.2.2 IL-33 inhibitors

9.2.3 PDE inhibitors

9.2.4 CFTR modulators

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AstraZeneca

10.4 Boehringer Ingelheim

10.5 Chiesi

10.6 GlaxoSmithKline

10.7 Novartis

10.8 Sunovion

10.9 Theravance

10.1 Regeneron/Sanofi

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Forecast Based on CAT Patient Population

11.1.3 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast Based on mMRC Patient Population

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Diagnosed Prevalent Cases of COPD by Severity

12.3.4 Percent Drug-Treated Patients

12.3.5 Drugs Included in Each Therapeutic Class

12.3.6 Launch and Patent Expiry Dates

12.3.7 General Pricing Assumptions

12.3.8 Individual Drug Assumptions

12.3.9 Generic Erosion

12.3.10 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: COPD: Key Metrics in the 7MM

Table 2: GOLD Criteria for the Classification of COPD, 2018

Table 3: Symptoms of COPD

Table 4: Modified mMRC Dyspnea Scale

Table 5: Risk Factors and Comorbidities for COPD

Table 6: Treatment Guidelines for COPD

Table 7: Country Profile – US, 2018

Table 8: Region Profile – 5EU, 2018

Table 9: Country Profile – Japan, 2018

Table 10: Leading Treatments for COPD, 2018

Table 11: Comparison of Therapeutic Classes in Development for COPD, 2018–2028

Table 12: AstraZeneca’s COPD Portfolio Assessment, 2019

Table 13: Chiesi’s COPD Portfolio Assessment, 2019

Table 14: GSK’s COPD Portfolio Assessment, 2019

Table 15: Novartis’ COPD Portfolio Assessment, 2019

Table 16: Sunovion’s COPD Portfolio Assessment, 2019

Table 17: Sunovion’s COPD Portfolio Assessment, 2019

Table 18: Theravance’s COPD Portfolio Assessment, 2019

Table 19: COPD Market – Global Drivers and Barriers, 2018–2028

Table 20: Key Events Impacting Sales for COPD in the US, 2018–2028

Table 21: COPD Market – Drivers and Barriers in the US, 2018–2028

Table 22: Key Events Impacting Sales for COPD in the 5EU, 2018–2028

Table 23: COPD Market – Drivers and Barriers in the 5EU, 2018–2028

Table 24: Key Events Impacting Sales for COPD in the Japan, 2018–2028

Table 25: COPD Market – Global Drivers and Barriers in Japan, 2018–2028

Table 26: Historical and projected launch dates for COPD across the 7MM, 2018–2028

Table 27: Historical and projected expiry dates for COPD across the 7MM, 2018–2028

Table 28: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figures

Figure 1: Global Sales Forecast by Country for COPD in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in COPD for the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of COPD During the Forecast Period

Figure 4: Normal Lungs and Lungs with COPD

Figure 5: The Pathogenesis of COPD

Figure 6: Refined ABCD Assessment Tool for COPD, 2018

Figure 7: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018

Figure 8: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018

Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD

Figure 10: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD

Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity

Figure 12: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years

Figure 13: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018

Figure 14: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018

Figure 15: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years

Figure 16: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018

Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018

Figure 18: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores – GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018

Figure 19: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores – GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018

Figure 20: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores – GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018

Figure 21: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores – GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018

Figure 22: COPD Treatment Algorithm

Figure 23: Unmet Needs and Opportunities in COPD

Figure 24: Overview of the Development Pipeline in COPD

Figure 25: Key Phase II/III Trials for Promising Pipeline Agents

Figure 26: Competitive Assessment of Late-Stage Pipeline Agents for COPD

Figure 27: Analysis of the Company Portfolio Gap in COPD During the Forecast Period

Figure 28: Global Sales for COPD by Country, 2018 and 2028

Figure 29: Sales for COPD by Drug Class in the US, 2018 and 2028

Figure 30: Sales for COPD by Drug Class in the 5EU, 2018 and 2028

Figure 31: Sales for COPD by Drug Class in Japan, 2018 and 2028

Frequently asked questions

Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.